VIP (Vasoactive Intestinal Peptide)

Literature widely indicates a very short plasma half-life of 1-2 minutes.

Given its very short half-life, consistent and frequent administration is commonly discussed in research protocols to maintain potential therapeutic levels.

• Blood Pressure Lowering Medications

  VIP has vasodilatory properties and can lower blood pressure. Concomitant use with antihypertensive drugs may lead to additive hypotensive effects. Monitoring of blood pressure is commonly advised.

  Use Caution

• Immunosuppressants

  VIP has immunomodulatory effects. While it often reduces inflammation, its interaction with conventional immunosuppressive therapies is complex and warrants careful monitoring in research settings.

  Monitor Combination

• Bronchodilators

  VIP has intrinsic bronchodilatory activity. In research for respiratory conditions, it may act synergistically with other bronchodilators, potentially enhancing airway opening.

  Synergistic

• Glucocorticoids

  Both VIP and glucocorticoids possess anti-inflammatory actions. Their combined use in research requires careful assessment of efficacy and potential for additive or synergistic effects on inflammation and immune responses.

  Monitor Combination

• Cholinergic Agents

  VIP can interact with the cholinergic system. Researchers commonly monitor for potential antagonistic or synergistic effects on smooth muscle and glandular secretions.

  Use Caution

1. 1Gather lyophilized VIP vial, bacteriostatic water for injection or sterile saline, and sterile syringes/needles.
2. 2Carefully remove the cap from the VIP vial and wipe the rubber stopper with an alcohol swab.
3. 3Draw the appropriate amount of diluent (e.g., 1-2 mL) into a sterile syringe.
4. 4Slowly inject the diluent into the VIP vial, aiming the stream at the side of the vial to avoid direct contact with the peptide powder.
5. 5Gently swirl the vial to dissolve the powder. Do not shake vigorously, as this can degrade the peptide.
6. 6Once fully dissolved, transfer the reconstituted solution into a sterile nasal spray bottle designed for accurate dose delivery.

For nasal administration, VIP is typically reconstituted with sterile water or saline to achieve the desired concentration for nasal spray application. A specific nasal spray device is commonly discussed for accurate dosing.

• Weeks 1-2: Initial systemic effects, such as mild transient flushing or changes in nasal sensation, may be noticed. Some individuals report a sense of calm or subtle improvements in energy.
• Weeks 3-6: More consistent improvements in inflammatory markers or symptom severity related to the research indication may begin to emerge. Gastrointestinal effects, if applicable, might start to stabilize.
• Months 1-3: Continued observation for more substantial and sustained benefits in immune modulation and anti-inflammatory responses. Functional improvements in areas like cognitive function or lung capacity may be reported.
• Months 3-6: Long-term assessment of the peptide's impact on chronic conditions. Maintenance protocols may be discussed based on individual responses and ongoing research objectives.
• Beyond 6 months: Continued monitoring for sustained benefits and potential need for dose adjustments or cyclical administration, as per specific research design.